Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. ( (JP:4882) ) has shared an announcement.
Perseus Proteomics, Inc. has announced an extension of the Phase I/II clinical trial period for its anti-transferrin receptor 1 antibody, PPMX-T003, targeting aggressive NK-cell leukemia, due to difficulties in patient enrollment. The trial will now continue until March 31, 2027, with the potential impact on the company’s business performance still under review.
More about Perseus Proteomics, Inc.
Perseus Proteomics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is engaged in creating innovative treatments for rare and challenging diseases, with a particular emphasis on aggressive NK-cell leukemia.
Average Trading Volume: 308,386
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.59B
For a thorough assessment of 4882 stock, go to TipRanks’ Stock Analysis page.